Snapshot from Aug 07, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Lupin spins out oncology programs to Kaveri
Business corporate spin-out

Lupin spins out oncology programs to Kaveri

Analysis based on 9 articles · First reported Jul 21, 2026 · Last updated Jul 21, 2026

Sentiment
40
Attention
3
Articles
9
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The spin-out allows Lupin to focus on core operations while retaining upside through equity in Kaveri. Positive clinical data may enhance valuation of the programs and attract investment to Kaveri.

Pharmaceuticals Biotechnology
Event Summary

Lupin (company) announced the strategic spin-out of two oncology programs, LNP7457 (PRMT5) and LNP8701 (SOS1), through its wholly owned subsidiary Lupin Inc. into Bicara Therapeutics Inc., a U.S.-based clinical-stage oncology company. Under the agreement, Lupin Inc. will hold a significant equity stake in Kaveri, provide seed funding, and grant exclusive rights to the programs. Kaveri will operate independently under CEO Kristi Jones and CMO Dr. Robert Pierce, and will seek additional capital to fund global clinical trials. Both programs have shown positive data at ASCO meetings in 2025 and 2026.

Key Actions
90 Lupin (company) spun out Bicara Therapeutics
70 Lupin (company) provided seed funding Bicara Therapeutics
60 Bicara Therapeutics completed financing round
Entities Involved
stock
Lupin (company)
Lupin spins out two oncology assets to Kaveri, retaining significant equity and providing seed funding, which may streamline its pipeline and create value.
Importance 100.0 Sentiment 40.0
priv
Bicara Therapeutics
Kaveri receives exclusive rights to two promising oncology programs and seed funding, positioning it to advance clinical trials and raise additional capital.
Importance 90.0 Sentiment 60.0
per
Vinita Gupta
As CEO of Lupin, Vinita Gupta announced the spin-out, highlighting the company's commitment to oncology innovation.
Importance 30.0 Sentiment 20.0
per
Kristi Jones
Kristi Jones is appointed CEO of Kaveri, bringing leadership to advance the oncology programs.
Importance 20.0 Sentiment 20.0
per
Robert Pierce
Dr. Robert Pierce serves as CMO of Kaveri, leading clinical development strategy.
Importance 15.0 Sentiment 15.0
ngo
American Society of Clinical Oncology
ASCO meetings provided the platform where positive data for the programs were presented, validating their potential.
Importance 10.0 Sentiment 10.0
cnt
United States
Kaveri is based in the U.S., where clinical trials will be conducted.
Importance 5.0 Sentiment 5.0
cnt
India
Lupin is headquartered in India, and the spin-out reflects its global strategy.
Importance 5.0 Sentiment 5.0
Relationships
Lupin (company) related ↔ United States
Lupin (company) related ↔ India
American Society of Clinical Oncology related ↔ United States
United States strategic partners ↔ India The US considers India a key strategic partner in the Indo-Pacific, pursuing extensive defense and technology cooperatio
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.